Tags

Type your tag names separated by a space and hit enter

[Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen].
Zhonghua Xue Ye Xue Za Zhi. 2019 Oct 14; 40(10):827-830.ZX

Abstract

Objective:

To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) containing cladribine sequential busulfan regimen for refractory/relapsed acute myeloid leukemia (AML) .

Methods:

The clinical data of 12 refractory/relapsed AML patients received allo-HSCT with cladribine sequential busulfan regimen.

Results:

① Of the 12 patients, 9 were males and 3 females, with a median age of 36 (27-50) years. The donors were identical sibling (3) , matched unrelated (1) and haploidentical family member (9) respectively. Nine patients reached partial remission and other remained no remission after chemotherapy before allo-HSCT. The median previous chemotherapy courses before allo-HSCT were 6 (2-13) . ② Conditioning regimen: Smostine 250 mg·m(-2)·d(-1), d-7; Cladribine 5 mg·m(-2)·d(-1), d-6 to d-2; Cytarabine Arabinoside 2 g·m(-2)·d(-1), d-6 to d-2; Busulfan 3.2 mg·m(-2)·d(-1), d-6 to d-3; Rabbit anti-human thymocyte immunoglobulin (ATG) 1.5 mg·m(-2)·d(-1) (unrelated donor transplantation) or 2.0-2.5 mg·m(-2)·d(-1) (haplo-HSCT) , d-4 to d-1. ③ Of the 12 patients, 11 patients attained complete haploidentical engraftment, one case occurred primary graft failure. The median durations for neutrophils and platelet implantations were 15 (15-21) and 19 (17-30) days respectively. ④After conditioning, no hepatic veno-occlusive diseases were observed, hemorrhagic cystitis occurred in 2 patients, 8 patients had fever, 3 cases experienced acute GVHD grade II, localized chronic GVHD occurred in 8 patients. ⑤The median follow-up was 8 (4-12) months. Leukemia relapse occurred in 2 patients at time of 6, 12 months after allo-HSCT. The estimated 1-year OS and DFS were (71.1±1.8) % and (62.2±1.8) %, respectively.

Conclusions:

allo-HSCT with cladribine sequential busulfan regimen was a feasible choice with favorable outcome for refractory/relapsed AML.

Authors+Show Affiliations

Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

chi

PubMed ID

31775481

Citation

Ai, H, et al. "[Clinical Observation of 12 Patients With Refractory/relapsed Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation Containing Cladribine Regimen]." Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 40, no. 10, 2019, pp. 827-830.
Ai H, Fu YW, Wang YQ, et al. [Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen]. Zhonghua Xue Ye Xue Za Zhi. 2019;40(10):827-830.
Ai, H., Fu, Y. W., Wang, Y. Q., Wei, X. D., & Song, Y. P. (2019). [Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 40(10), 827-830. https://doi.org/10.3760/cma.j.issn.0253-2727.2019.10.006
Ai H, et al. [Clinical Observation of 12 Patients With Refractory/relapsed Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation Containing Cladribine Regimen]. Zhonghua Xue Ye Xue Za Zhi. 2019 Oct 14;40(10):827-830. PubMed PMID: 31775481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen]. AU - Ai,H, AU - Fu,Y W, AU - Wang,Y Q, AU - Wei,X D, AU - Song,Y P, PY - 2019/11/29/entrez PY - 2019/11/30/pubmed PY - 2019/12/18/medline KW - Acute myeloid leukemia KW - Allogeneic hematopoietic stem cell transplantation KW - Cladribine SP - 827 EP - 830 JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JO - Zhonghua Xue Ye Xue Za Zhi VL - 40 IS - 10 N2 - Objective: To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) containing cladribine sequential busulfan regimen for refractory/relapsed acute myeloid leukemia (AML) . Methods: The clinical data of 12 refractory/relapsed AML patients received allo-HSCT with cladribine sequential busulfan regimen. Results: ① Of the 12 patients, 9 were males and 3 females, with a median age of 36 (27-50) years. The donors were identical sibling (3) , matched unrelated (1) and haploidentical family member (9) respectively. Nine patients reached partial remission and other remained no remission after chemotherapy before allo-HSCT. The median previous chemotherapy courses before allo-HSCT were 6 (2-13) . ② Conditioning regimen: Smostine 250 mg·m(-2)·d(-1), d-7; Cladribine 5 mg·m(-2)·d(-1), d-6 to d-2; Cytarabine Arabinoside 2 g·m(-2)·d(-1), d-6 to d-2; Busulfan 3.2 mg·m(-2)·d(-1), d-6 to d-3; Rabbit anti-human thymocyte immunoglobulin (ATG) 1.5 mg·m(-2)·d(-1) (unrelated donor transplantation) or 2.0-2.5 mg·m(-2)·d(-1) (haplo-HSCT) , d-4 to d-1. ③ Of the 12 patients, 11 patients attained complete haploidentical engraftment, one case occurred primary graft failure. The median durations for neutrophils and platelet implantations were 15 (15-21) and 19 (17-30) days respectively. ④After conditioning, no hepatic veno-occlusive diseases were observed, hemorrhagic cystitis occurred in 2 patients, 8 patients had fever, 3 cases experienced acute GVHD grade II, localized chronic GVHD occurred in 8 patients. ⑤The median follow-up was 8 (4-12) months. Leukemia relapse occurred in 2 patients at time of 6, 12 months after allo-HSCT. The estimated 1-year OS and DFS were (71.1±1.8) % and (62.2±1.8) %, respectively. Conclusions: allo-HSCT with cladribine sequential busulfan regimen was a feasible choice with favorable outcome for refractory/relapsed AML. SN - 0253-2727 UR - https://www.unboundmedicine.com/medline/citation/31775481/[Clinical_observation_of_12_patients_with_refractory/relapsed_acute_myeloid_leukemia_treated_with_allogeneic_hematopoietic_stem_cell_transplantation_containing_cladribine_regimen]_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31775481/ DB - PRIME DP - Unbound Medicine ER -